AstraZeneca’s next-gen SERD Etcamah disappoints in untreated advanced breast cancer

AstraZeneca said Friday that its recently approved breast cancer drug Etcamah failed a late-stage trial designed to support a label expansion into an earlier setting. Just last week, the FDA cleared the ...